Alirocumab reduces MIs

MDedge Cardiocast

This week in clinical cardiology:

1. Alirocumab reduces both type 1 and 2 MIs.
2. Despite failed primary endpoint, MI alert device has predictive value.
3. Look for alcohol septal ablation in the next HOCM guideline.
4. FDA: Forty ARBs free of nitrosamines.

You can contact the Cardiocast with ideas, suggestions, stories, or questions for Dr. Dwyer by emailing us at [e-mail] and you can follow MDedge Cardiology on Twitter at @MDedgeCardio.